Recentin (cediranib) / AstraZeneca 
Welcome,         Profile    Billing    Logout  
 288 Diseases   30 Trials   30 Trials   848 News 
36 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Recentin (cediranib) / AstraZeneca
ACTRN12610000160033: A randomised, placebo-controlled, trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and concurrent and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer.

Active, not recruiting
3
500
 
AstraZenica, Medical Research Council Clinical Trial Unit
Platinum sensitive relapsed ovarian cancer
 
 
ACTRN12618000498291: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients.

Recruiting
3
110
 
The University of Sydney, Cancer Australia, AstraZeneca, Cancer Research UK
Ovarian Cancer, Fallopian tube Cancer, Peritoneal Cancer
 
 
2007-006250-25: A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN™) (30 mg) When Added to Gemcitabine and Cisplatin versus the Efficacy of Placebo When Added to Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

 
3
60
Europe
RECENTIN, AZD2171,
ASTRAZENECA
Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
 
 
2017-000161-75: ICON9 is a research study investigating patients with recurrent ovarian, fallopian tube or primary peritoneal cancer, who have had their tumour shrunk by chemotherapy. The study will address whether such patients may benefit from maintenance treatment with two new anti-cancer, orally-administrated drugs called olaparib and cediranib.

Not yet recruiting
3
618
Europe
Olaparib, Cediranib, AZD2171 Maleate, Film-coated tablet, Lynparza
University College London, Cancer Research UK, AstraZeneca UK Limited
High grade serous or endometrioid ovarian, fallopian and peritoneal cancer, Ovarian, fallopian and peritoneal cancer, Diseases [C] - Cancer [C04]
 
 
NRG-GY004, NCT02446600: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Checkmark From GY004 trial in combination with cediranib for recurrent platinum sensitive ovarian cancer
Mar 2020 - Mar 2020: From GY004 trial in combination with cediranib for recurrent platinum sensitive ovarian cancer
Active, not recruiting
3
579
Canada, Japan, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), AstraZeneca, NRG Oncology
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
02/20
08/25
ICON9, NCT03278717: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London
Ovarian Cancer
12/23
12/23
COCOS, NCT02502266: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Hourglass Jul 2023 - Dec 2023 : Data from COCOS (GY005) trial trial in combination with Recentin for recurrent platinum r/r ovarian cancer
Active, not recruiting
2/3
587
Canada, Japan, US, RoW
Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Questionnaire Administration, Topotecan, Hycamptamine, Topotecan Lactone, Topotecan Hydrochloride, Evotopin, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI), Canadian Cancer Trials Group, NRG Oncology
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
06/23
07/25
ACTRN12612000020886: A trial of cediranib in the treatment of patients with alveolar soft part sarcoma

Recruiting
2
36
 
The Institute of Cancer Research / Royal Marsden Hospital NHS Foundation Trust (UK), Cancer Research UK, AstraZeneca
Alveolar soft part sarcoma
 
 
2015-003883-36: Feasibility of providing patients with platinum sensitive, high grade serous, BRCA mutated ovarian cancer with multiple treatments with olaparib after recurrence of their disease following treatment with platinum based chemotherapy.

Ongoing
2
26
Europe
Olaparib, Cediranib, AZD2281, AZD2171, Film-coated tablet, Lynparza
The Christie NHS Foundation Trust
platinum sensitive BRCAm high grade serous ovarian cancer, platinum sensitive BRCAm high grade serous ovarian cancer, Diseases [C] - Cancer [C04]
 
 
2016-003964-38: Clinical study, involving Italian clinical sites, comparing the activity of Paclitaxel (weekly administration) to the activity of Cediranib-Olaparib with continuous administration or to Cediranib-Olaparib with intermittent administration, in patients with advanced ovarian cancer, resistant to previous platinum treatment. Studio Barocco: Studio clinico che coinvolge più centri clinici italiani volto a comparare l’attività di paclitaxel somministrato settimanalmente con quella di cediranib e olaparib somministrati in modo continuo o cediranib e olaparib somministrati in modo intermittente, nelle pazienti con tumore dell’ovaio avanzato, resistente a trattamenti a base di platino.

Not yet recruiting
2
100
Europe
Cediranib, Olaparib, Paclitaxel, [Not Applicable], [Not applicable], [n.a.], Tablet, Solution for infusion, PACLITAXEL MYLAN GENERICS - 6 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 16.7 ML
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AstraZeneca S.p.A.
resistant high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. carcinoma epiteliale ovarico ad alto grado, carcinoma delle tube di falloppio e carcinoma peritoneale primitivo, resistente al platino., ovarian cancer, resistant to previous platinum treatment. tumore dell’ovaio avanzato, resistente al trattamento a base di platino., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
2016-004617-28: Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy?

Not yet recruiting
2
129
Europe
Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza)
The University of Manchester, AstraZeneca Ltd
Advanced or recurrent endometrial carcinoma or carcinosarcoma, Endometrial cancer, Diseases [C] - Cancer [C04]
 
 
2016-004618-93: Is it safe to add Cediranib to weekly paclitaxel chemotherapy in women with ovarian cancer who are at risk of developing malignant bowel obstruction?

Ongoing
2
30
Europe
Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza), Paclitaxel
University of Manchester, AstraZeneca
Platinum-Resistant Ovarian Cancer, Ovarian Cancer that has not responded to treatment with platinum containing chemotherapy., Diseases [C] - Cancer [C04]
 
 
2016-004215-13: Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer

Not yet recruiting
2
108
Europe
Cediranib, Olaparib, AZD2171, AZD2281, Film-coated tablet
The Clatterbridge Cancer Centre NHS Foundation, AstraZeneca
Advanced recurrent and metastatic cervical cancer., Cervical cancer which has come back or spread around the body., Diseases [C] - Cancer [C04]
 
 
NCT00942877: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Checkmark P2 data
Jun 2011 - Jun 2011: P2 data
Checkmark P2 data
May 2011 - May 2011: P2 data
Active, not recruiting
2
53
US
AZD2171, Cediranib
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
09/18
12/24
2018-003056-21: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.

Not yet recruiting
2
76
Europe
Olaparib, Cediranib, Durvalumab, Film-coated tablet, Concentrate for solution for injection/infusion
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, AstraZeneca, CRUK Cambridge Centre
Surgically resectable renal cell cancer (Stage M0/M1), Surgically resectable renal cell cancer (Stage M0/M1), Diseases [C] - Cancer [C04]
 
 
OCTOVA, NCT03117933 / 2016-000559-28: Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Completed
2
139
Europe
Olaparib, Cediranib, Paclitaxel
University of Oxford, AstraZeneca
Ovarian Cancer
03/21
12/23
COMICE, NCT04487587: A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer

Recruiting
2
108
Europe
Cediranib, Olaparib
The Clatterbridge Cancer Centre NHS Foundation Trust, University of Liverpool
Cervical Cancer
08/21
09/21
NCT02345265: Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

Active, not recruiting
2
70
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Questionnaire Administration
National Cancer Institute (NCI)
Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
07/22
08/25
AMBITION, NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer

Recruiting
2
104
RoW
olaparib+cediranib combination therapy, durvalumab + olaparib combination therapy, durvalumab + chemotherapy treatment, durvalumab + tremelimumab + chemotherapy treatment, durvalumab + tremelimumab + paclitaxel treatment, durvalumab +chemotherapy treatment
Yonsei University, AstraZeneca, Samsung Genomic Institute, Seoul National University Hospital, Samsung Medical Center, Korean Gynecologic Oncology Group
Platinum-resistant Recurrent Ovarian Cancer
09/22
09/22
NCT02974621: Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Active, not recruiting
2
70
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Onbevzi, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Recurrent Glioblastoma
12/22
07/25
COPELIA, NCT03570437: Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Active, not recruiting
2
124
Europe
Paclitaxel, L01CD01, Cediranib, AZD2171, 288383-20-0, Olaparib, AZD2281, Lynparza, L01XX46
University of Manchester, AstraZeneca, Cardiff University
Carcinosarcoma, Endometrial Neoplasms
01/23
06/23
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
NRG-GY023, NCT04739800: Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Active, not recruiting
2
120
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Computed Tomography with Contrast, Contrast Enhanced Computed Tomography, CONTRAST ENHANCED CT SCAN, Contrast-enhanced Computed Tomography, CT Scan With Contrast, CT with Contrast, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Topotecan Hydrochloride, Evotopin, Hycamptamine, Hycamtin, Nogitecan Hydrochloride, Potactasol, SKF S 104864 A, SKF S-104864-A, SKF S104864A, Topotec, Topotecan HCl, topotecan hydrochloride (oral)
National Cancer Institute (NCI), NRG Oncology
Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube High Grade Serous Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian High Grade Serous Adenocarcinoma, Refractory Ovarian Low Grade Serous Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma
01/23
06/25
NCI-2015-01097, NCT02498613: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Active, not recruiting
2
122
Canada, US
18F-Fluoromisonidazole, 18F-MISO, 18F-Misonidazole, FLUOROMISONIDAZOLE F-18, FMISO, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI), AstraZeneca
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage III Lung Small Cell Carcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Unresectable Triple-Negative Breast Carcinoma
06/22
04/25
NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Active, not recruiting
2
90
US
Cediranib, AZ-D2171, AZD 2171, AZD2171, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma With Neuroendocrine Differentiation, Stage IV Prostate Adenocarcinoma AJCC v7
03/23
06/25
NCT01391962: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Active, not recruiting
2
34
US
Cediranib, AZD2171 maleate, Recentin, AXD2171, Sunitinib, Sutent, SU11248, SU011248, Prochlorperazine, Compro, Promethazine, Phenadoz, Phenergan, Promethegan, Benzodiazepine, Valium, Diazepam, Estazolam, ProSom, Flurazepam, Dalmane, Lorazepam, Ativan, Filgrastim, Neupogen, Sargramostim, Leukine, Lomotil, Diphenoxylate hydrochloride (HCL)/atropine, Loperamide, Imodium, Diamode, Anti-Diarrheal (loperamide), Vitamin B6, Pyridoxine, Aquaphor, Acetaminophen, Tylenol, Ofirmev, FeverAll, Levothyroxine, Synthroid, Tirosint, Unithroid, Warfarin, Coumadin
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
11/23
03/25
NCI-2017-01672, NCT03660826: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Active, not recruiting
2
288
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Capivasertib, AZD 5363, AZD-5363, AZD5363, Truqap, Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI), NRG Oncology
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Cancer AJCC v8
12/24
12/24
HUDSON, NCT03334617 / 2017-002208-28: Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Calendar Jan 2024 - Dec 2024: Data from HUDSON trial for NSCLC
Active, not recruiting
2
531
Europe, Canada, US, RoW
Durvalumab, AZD9150, AZD6738, Vistusertib, Olaparib, Oleclumab, trastuzumab deruxtecan, cediranib, AZD6738 (ceralasertib), AZD6738 (ceralasertib) (240 mg or 160 mg), AZD6738 (ceralasertib) 7 days monotherapy
AstraZeneca
Non-Small Cell Lung Cancer
09/24
09/24
NCI-2019-04148, NCT04090567: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Recruiting
2
60
US
Cediranib, AZD2171, Ceralasertib, AZD6738, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
03/25
03/25
WIRE, NCT03741426: - Novel Treatments in Renal Cell Cancer

Recruiting
2
60
Europe
Olaparib, AZD2281, KU-0059436, LYNPARZA, Cediranib, AZD2171, Durvalumab, MEDI4736
CCTU- Cancer Theme, University of Cambridge, AstraZeneca, Cancer Research UK
Renal Cell Cancer
11/25
11/25
SWOG S0905, NCT01064648: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Active, not recruiting
1/2
117
US
Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration
National Cancer Institute (NCI)
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
06/18
03/25
NCT01116648: Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark Cediranib+olaparib vs. olaparib alone for women with recurrent platinum-sensitive ovarian cancer
Sep 2014 - Sep 2014: Cediranib+olaparib vs. olaparib alone for women with recurrent platinum-sensitive ovarian cancer
Checkmark In pts with recurrent ovarian, fallopian tube, peritoneal cancer
More
Active, not recruiting
1/2
155
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Triple-Negative Breast Carcinoma
10/18
02/25
NCT02484404: Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Recruiting
1/2
384
US
Olaparib, Cediranib, Durvalumab
National Cancer Institute (NCI)
Colorectal Neoplasms, Breast Neoplasms
12/24
12/25
NCT00750841: Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

Active, not recruiting
1
64
Europe, Canada
cediranib, RECENTIN
AstraZeneca
Solid Tumors
07/09
12/24
NCT02876068: Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies

Active, not recruiting
1
19
US
Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, ARRY-142886, AZD6244, MEK Inhibitor AZD6244
Mayo Clinic, National Cancer Institute (NCI)
Solid Neoplasm, Stage IV Skin Melanoma
06/16
 
NCT01364051: Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Active, not recruiting
1
19
US
Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, ARRY-142886, AZD 6244, AZD-6244, AZD6244, MEK Inhibitor AZD6244, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate
National Cancer Institute (NCI)
Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm
06/19
03/25

Download Options